Gren Z. Wang

发表

Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Aminomethylpiperazines as selective urotensin antagonists.

D. Behm, S. Douglas, Zining Wu, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, M. Convery, 2019, Journal of medicinal chemistry.

Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.

P. Lam, D. Cheney, K. He, 2007, Bioorganic & medicinal chemistry letters.

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

J. Briand, C. Chung, N. Varga, 2011, Bioorganic & medicinal chemistry letters.

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.

Chong-Hwan Chang, Daniel L Cheney, Chong-Hwan Chang, 2007, Bioorganic & medicinal chemistry letters.

Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.

S. Semus, D. Behm, R. Bentley, 2008, Journal of medicinal chemistry.

Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.

S. Semus, D. Behm, R. Bentley, 2007, Journal of medicinal chemistry.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

J. Bertin, K. Erhard, D. Lipshutz, 2019 .

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

J. Bertin, M. Convery, D. Lipshutz, 2018, ACS medicinal chemistry letters.

Development of potent and selective small-molecule human Urotensin-II antagonists.

N. Aiyar, D. Behm, S. Douglas, 2008, Bioorganic & medicinal chemistry letters.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Carol A. Capriotti, J. Bertin, M. Convery, 2018, ACS medicinal chemistry letters.